ARTICLE | Clinical News
VitrenAse: Phase II
August 19, 2002 7:00 AM UTC
Immusol began a double-blind U.S. Phase II trial of its VitrenAse to treat PVR, a condition characterized by uncontrolled cellular growth, retinal detachment and vision loss. The trial will assess saf...